Clinical recommendations for perioperative immunotherapy‐induced adverse events in patients with non‐small cell lung cancer

Clinical recommendations for perioperative immunotherapy‐induced adverse events in patients with non‐small cell lung cancer

Show other versions (1)

Abstract Perioperative adjuvant treatment has become an increasingly important aspect of the management of patients with non‐small cell lung cancer (NSCLC). In particular, the success of immune checkpoint inhibitors, such as antibodies against PD‐1 and PD‐L1, in patients with lung cancer has increas...

Full description

Bibliographic Details
Main Authors: Jun Ni, Miao Huang, Li Zhang, Nan Wu, Chun‐Xue Bai, Liang‐An Chen, Jun Liang, Qian Liu, Jie Wang, Yi‐Long Wu, Feng‐Chun Zhang, Shu‐Yang Zhang, Chun Chen, Jun Chen, Wen‐Tao Fang, Shu‐Geng Gao, Jian Hu, Tao Jiang, Shan‐Qing Li, He‐Cheng Li, Yong‐De Liao, Yang Liu, De‐Ruo Liu, Hong‐Xu Liu, Jian‐Yang Liu, Lun‐Xu Liu, Meng‐Zhao Wang, Chang‐Li Wang, Fan Yang, Yue Yang, Lan‐Jun Zhang, Xiu‐Yi Zhi, Wen‐Zhao Zhong, Yu‐Zhou Guan, Xiao‐Xiao Guo, Chun‐Xia He, Shao‐Lei Li, Yue Li, Nai‐Xin Liang, Fang‐Liang Lu, Chao Lv, Wei Lv, Xiao‐Yan Si, Feng‐Wei Tan, Han‐Ping Wang, Jiang‐Shan Wang, Shi Yan, Hua‐Xia Yang, Hui‐Juan Zhu, Jun‐Ling Zhuang, Ming‐Lei Zhuo
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Thoracic Cancer
Subjects:
clinical recommendation
irAE
non‐small cell lung cancer
perioperative immunotherapy
Online Access:https://doi.org/10.1111/1759-7714.13942

Internet

https://doi.org/10.1111/1759-7714.13942

Similar Items